Clinical Evidence: Weight Loss
Phase 2 trial data, dose-response curves, and the TRIUMPH Phase 3 program
The Trial Data
In 2023, the New England Journal of Medicine published the Phase 2 retatrutide results that stunned the obesity field: participants on the highest dose lost an average of 24.2% of their body weight in just 48 weeks -- the most ever recorded for an injectable anti-obesity medication. This unit walks you through the trial design, dose-response data, and what the Phase 3 TRIUMPH program aims to confirm.
Phase 2 Trial Design
Randomization, dose tiers, patient population, and endpoints.
Dose-Response Curve
Weight loss outcomes across 1mg, 4mg, 8mg, and 12mg dose tiers.
Headline Results
The key numbers: 24.2% mean weight loss, 100% of 12mg participants losing >5%.
Body Composition
Fat mass vs lean mass changes and what the data shows about muscle preservation.
The TRIUMPH Program
Phase 3 trial series design, timelines, and what needs to be confirmed.